{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-044533","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.098475+00:00","generated_at":"2026-05-30T02:15:06.290991+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Indaptus Q3 2024: EPS -$0.32, cash $7.4M; Decoy20 Phase 1 expands with BeiGene deal","bullets":["Q3 2024 net loss $0.32 per share (vs $0.47 loss in Q3 2023); nine-month loss $1.23 per share (vs $1.36 loss).","Cash and equivalents $7.4M at Sep 30, 2024, down from $13.4M at Dec 31, 2023; cash runway into Q1 2025.","Clinical supply agreement with BeiGene to combine Decoy20 with tislelizumab (anti-PD-1) for advanced solid tumors.","Phase 1 trial of Decoy20 now allows unrestricted enrollment for weekly dosing at lower dose; well tolerated.","R&D expenses decreased to $1.5M in Q3 2024 from $2.2M YoY; completed $3M registered direct offering in August 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-044533","json":"https://secwatch.observer/filing/0001493152-24-044533.json","markdown":"https://secwatch.observer/filing/0001493152-24-044533.md","text":"https://secwatch.observer/filing/0001493152-24-044533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224044533/0001493152-24-044533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224044533/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:15:06.290991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}